Safety, tolerability, pharmacodynamic effects and preliminary evidence for efficacy of the anti-hypertension vaccine CYT006-AngQb

Trial Profile

Safety, tolerability, pharmacodynamic effects and preliminary evidence for efficacy of the anti-hypertension vaccine CYT006-AngQb

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2012

At a glance

  • Drugs CYT 006 AngQb (Primary)
  • Indications Essential hypertension; Hypertension; Various toxicities
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cytos Biotechnology
  • Most Recent Events

    • 08 Mar 2008 Final results have been published in the Lancet.
    • 06 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top